Blood sugar improves with first gastrointestinal microbiome modulator, NM504
Tuesday, June 24, 2014 - 10:02
in Health & Medicine
In adults with prediabetes, a new drug that alters microbial populations and their environment in the gastrointestinal tract improves glucose tolerance -- the body's response to consuming carbohydrates -- after four weeks of treatment and without a change in diet. The not-yet-named therapeutic, NM504, is the first in a new class of therapies known as GI microbiome modulators. The GI microbiome -- the mix of microbial and associated physical and chemical factors in the digestive system -- may play a critical part in regulating the body's metabolism, some researchers believe.